Mirati Therapeutics, Inc.
MRTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -82.7% | 438.1% | 301.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 95.2% | -605.5% | -2,134.3% | -5,383.2% |
| R&D Expenses | $1 | $1 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $0 | $0 |
| Operating Income | -$1 | -$1 | -$0 | -$0 |
| % Margin | -6,108% | -795.1% | -2,756.9% | -6,659.8% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$1 | -$1 | -$0 | -$0 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | -$1 | -$1 | -$0 | -$0 |
| % Margin | -5,957.4% | -807% | -2,671.6% | -6,394.5% |
| EPS | -13.18 | -11.21 | -7.96 | -5.69 |
| % Growth | -17.6% | -40.8% | -39.9% | – |
| EPS Diluted | -13.18 | -11.21 | -7.96 | -5.69 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$0 | -$0 |
| % Margin | -6,084.4% | -792.6% | -2,752.1% | -6,652.3% |